Journal of Pharmacokinetics and Biopharmaceutics 2002: Vol 29 Table of Contents

5 Pages·2002·0.53 MB·English

Journal of Pharmacokinetics and Pharmacodynamics
Vol. 29, No. 1 February 2002
CONTENTS
PHARMACOKINETICS/PHARMACODYNAMICS
Fifth-Generation Model for Corticosteroid Pharmacodynamics:
Application to Steady-State Receptor Down-Regulation
and Enzyme Induction Patterns during Seven-day Con¬
tinuous Infusion of Methylprednisolone in Rats 1
Rohini Ramakrishnan, Debra C. DuBois, Richard R. Almon,
Nancy A. Pyszczynski, and William J. Jusko
Population Pharmacokinetic Analysis of the Major Metabolites of
Capecitabine 25
R. Gieschke, B. Reigner, K. S. Blesch, and J.-L. Steimer
Influence of Arterial vs. Venous Sampling Site on Nicotine Tolerance
Model Selection and Parameter Estimation 49
Franziska Schaedeli, Maria Pitsiu, Neal L. Benowitz,
Steven G. Gourlay, and Davide Verotta
PHARMACOMETRICS
Determination of an Optimal Dosage Regimen Using a Bayesian
Decision Analysis of Efficacy and Adverse Effect Data 67
Gordon Graham, Suneel Gupta, and Leon Aarons
LETTERS TO THE EDITOR
A Note on Sample Size Calculation in Bioequivalence Trials 89
Dieter Hauschke
Sample Size Calculation in Bioequivalence Trials 95
Peter Blood
Author’s Response 99
Hansheng Wang and Shein-Chung Chow
ERRATA 101
Journal of Pharmacokinetics and Pharmacodynamics
Vol. 29, No. 2 April 2002
CONTENTS
Pharmacodynamics and Pharmacogenomics of Diverse Receptor-
Mediated Effects of Methylprednisolone in Rats Using
Microarray Analysis 103
Richard R. Almon, Dehra C. DuBois, Emily H. Brandenburg,
Wei Shi, Shuzhong Zhang, Robert M. Straubinger,
and William J. Jusko
A Compartmental Model of Hepatic Disposition Kinetics I. Model
Development and Application to Linear Kinetics 131
Yuri G. Anissimov and Michael S. Roberts
Modeling the Influence of Growth Hormone on Lipolysis 157
Rik C. Schoemaker, Madelon M. Buijs, Hanno Fiji,
Jacobus Burggraaf, and Adam F. Cohen
Limited and Optimal Sampling Strategies for Etoposide and
Etoposide Catechol in Children with Leukemia 171
John Carl Panetta, Mark Wilkinson, Ching-Hon Pui, and
Mary V. Relling
Physiologic-Pharmacologic Interpretation of the Constants in the
Hill Equation for Neuromuscular Block; A Hypothesis 189
Vladimir Nigrovic and Amann Anton
Journal of Pharmacokinetics and Pharmacodynamics
Vol. 29, No. 3 June 2002
CONTENTS
Pharmacokinetic Modeling of Arsenite Uptake and Metabolism in
Hepatocytes—Mechanistic Insights and Implications for
Further Experiments 207
Michael R. Easterling, Miroslav Styblo, Marina V. Evans, and
Elaina M. Kenyon
Mechanism-based Pharmacodynamic Modeling of the Interaction of
Midazolam, Bretazenil, and Zolpidem with Ethanol 235
Bert Tuk, Toon van Goal, and Meindert Danhof
PHARMACOMETRICS
Assessment of Type I Error Rates for the Statistical Sub-model in
NONMEM 251
Ulrika Wdhlhy, M. Rene Boiiw, E. Niclas Jonsson, and
Mats O. Karlsson
Bayesin Analysis of Population PK/PD Models: General Concepts
and Software 271
David J. Lunn, Nicky Best, Andrew Thomas, Jon Wakefield, and
David Spiegelhalter
ERRATA 309
Journal of Pharmacokinetics and Pharmacodynamics
Vol/29, No. 4 August 2002
CONTENTS
Multiple-Pool Cell Lifespan Model of Hematologic ElTects of
Anticancer Agents 311
Wojciech Krzyzanski and William J. Jusko
Clinical Trial Simulation Using Therapeutic Effect Modeling:
Application to Ivabradine Efficacy in Patients with
Angina Pectoris 339
Sylvie Chahaud, Pascal Girard, Patrice Nony, and
Jean-Pierre Boissel
Gastric Acid Secretion in the Dog: A Mechanism-based Pharmaco¬
dynamic Model for Histamine Stimulation and
Irreversible Inhibition by Omeprazole 365
Angela Abeld, Bjorn Holstein, UlfG. Eriksson, Johan Gabrielsson,
and Mats O. Karlsson
Modeling Nicotine Arterial-Venous Differences to Predict Arterial
Concentrations and Input Based on Venous
Measurements: Application to Smokeless Tobacco and
Nicotine Gum 383
Maria Pitsiu, Jean-Michel Gries, Neal Benowitz,
Steven G. Gourlay, and Davide Verotta
COMMENTARY
Commentary on Significance Levels for Covariate Effects in
NONMEM 403
Stuart L. Beal
Reply to Commentary 411
Ulrika Wdhlby, E. Niclas Jonsson, and Mats O. Karlsson
ANNOUNCEMENT
Pharmacokinetic-Pharmacodynamic Modeling: Concepts and
Applications 413
Journal of Pharmacokinetics and Pharmacodynamics
Vol. 29, No. 5/6 December 2002
CONTENTS
Pharmacokinetics, Biologic Activity, and Tolerability of Alefacept
by Intravenous and Intramuscular Administration 415
Akshay K. Vaishnaw and Christopher N. TenHoor
A System-Approach Method for the Adjustment of Time-Varying
Continuous Drug Infusion in Individual Patients: A
Simulation Study 427
Maria Durisovd and Ladislav Dedik
PHARMACOMETRICS
Nonparametric AUC Estimation in Population Studies with Incom¬
plete Sampling: A Bayesian Approach 445
P. Magni, R. Bellazzi, G. De Nicolao, /. Poggesi, and
M. Rocchetti
Use of Prior Information to Stabilize a Population Data Analysis 473
Per O. Gisleskog, Mats O. Karlsson, and Stuart L. Beal
ANNOUNCEMENTS
Workshop in Basic Pharmacokinetics 507
Author Index to Volume 29 509
Subject Index to Volume 29 511